A study uncovers IL-1β signaling in cardiac fibrosis, highlighting distinct fibroblast populations and promising ...

The SOUL cardiovascular outcomes trial was a double-blinded, randomised trial that compared oral semaglutide to placebo as an ...

According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...

Myocardial infarction or 'heart attack' is a type of acute coronary syndrome in which sudden blockage of a coronary artery, and subsequent myocardial ischaemia, results in damage to the ...

Adhering to the Mediterranean diet reduces the risk of developing a second cardiometabolic disease, especially over shorter ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, ...

(Editor's note: The NCDR-Action Registry will incorporate and replace the National Registry of Myocardial Infarction, which has collected data on more than 2.3 million acute MI patients and helped ...

BAGSVAERD, Denmark I1, 2024 I Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a ...

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug ...